Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New spinout enterprise from Oxford seeks to accelerate evidence based innovation for treatments and services in mental health and dementia.

Image of a monitor with code displayed on the screen.

Cristal Health (established in May 2019) has been developed as a sustainable way to accelerate the UK-CRIS programme. The UK-CRIS network operates a managed service for secure access to one of the world's largest repositories of de-identified patient data relating to mental health and dementia conditions.

 

Cristal Health presents a real opportunity for accelerating and translating new discovery medicine, including prevention and treatment, into better health outcomes for sufferers of mental illness and their familiesMike Denis, CEO, Cristal Health.

 

Mike Denis, CEO, Cristal Health, said,

"I'm honoured to be leading the team in the joint partnership between the NHS and academia working with industry using real world health data. We're able to add value by continually enriching the clinical content available to clinicians, researchers and scientists which will truly deliver many more opportunities to predict, identify, prevent or manage mental health conditions in the UK."

 

 

The spinning out of remarkable new companies like Cristal Health is great news. It brings in investment which allows for exciting initiatives and innovative activity developed in the NHS and Universities to grow more quickly and become sustainable. Everyone benefits and most importantly our patients.Professor John Geddes, Head of Department of Psychiatry, University of Oxford.

The market for real world evidence and data is projected to grow as organisations seek to reduce costs and time, technology and modelling becomes more widely available and data custodians realise the benefits of facilitating secure access to de-identified data.

Cristal Health will focus on three areas:

• developing offerings to help in early stage drug discovery, reduce clinical trial costs by 12-30%, support post launch and Phase IV evaluation (i.e. following approval) and pharmacovigilance (safety monitoring)

• supporting NHS Trusts in generating revenue from increased participation in the global trials market and developing tools that support service reviews through ongoing monitoring

• and supporting academic research by developing tools to support text-mining to create real knowledge from distributed and heterogeneous data.

Cristal Health will use any profits generated to re-invest into its core purpose of accelerating improvements in medical research, services and outcomes for patients with a mental illness and/or dementia.

To find out more about Cristal Health contact: CEO, Mike Denis, Mike@cristalhealth.co.uk or CIO David, Newton, David@cristalhealth.co.uk.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

New Study Shows Simvastatin Can Change the Way People Experience Certain Emotions

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Anxiety Disorders Among Children, Assessment and Working with Families

Anxiety disorders are the most common mental health disorders among children, yet there is limited guidance on the process of assessing child anxiety disorders and sharing diagnostic outcomes with families.

Landmark New Clinical Trial Shows Benefits of Automated Virtual Reality (VR) Treatment for Severe Psychological Problems

The gameChange automated VR program is designed to treat agoraphobia in patients with psychosis. In the largest ever clinical trial of virtual reality for mental health, gameChange especially helped people whose anxiety had previously left them virtually housebound.

UK-Japanese Collaboration Researches Mental Health Challenges Faced by Young People and their Families

Dr Simona Skripkauskaite, Departments of Psychiatry and Experimental Psychology, University of Oxford, is the UK lead for one of the ten collaborative research projects jointly awarded by the Economic and Social Research Council (ESRC), the Arts and Humanities Research Council (AHRC) and the Japan Society for the Promotion of Science (JSPS), to address the challenges presented by the global pandemic.

Department of Psychiatry Recognition Awards

Today we announce the prize winners of the first Department of Psychiatry Recognition Awards. One award is designed to offer early career researchers (ECRs) the opportunity to showcase their work, motivations and aspirations for research into mental health. Alongside this we launch the 'Good Citizen' award, where all department members have been able to make nominations.